4-(6-chloropyridazine-3-yl)-7-methoxy-2-isopropyl-pyrazolo[1,5-a]pyridine | 909720-28-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(6-chloropyridazine-3-yl)-7-methoxy-2-isopropyl-pyrazolo[1,5-a]pyridine
• 英文别名: 4-(6-Chloropyridazin-3-yl)-2-isopropyl-7-methoxypyrazolo[1,5-a]pyridine；4-(6-chloropyridazin-3-yl)-7-methoxy-2-propan-2-ylpyrazolo[1,5-a]pyridine
• CAS: 909720-28-1
• 化学式: C₁₅H₁₅ClN₄O
• 分子量: 302.763
• InChiKey: AONRSMASUDPLCX-UHFFFAOYSA-N

物化性质

• 密度：
  1.33±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(6-chloropyridazine-3-yl)-7-methoxy-2-isopropyl-pyrazolo[1,5-a]pyridine 在 溶剂黄146 作用下， 反应 3.0h， 生成 6-(7-methoxy-2-isopropylpyrazolo[1,5-a]pyridine-4-yl)-3(2H)pyridazinone
  参考文献：
  名称：

  Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient

  摘要：

  新型吡唑吡啶-4-基吡啉酮衍生物作为磷酸二酯酶抑制剂，并且是用于制药产品的有用化合物。具体来说，本发明的化合物是由以下一般式（1）表示的吡唑吡啶-4-基吡啉酮衍生物（例如：6-(2-乙基-7-甲氧基吡唑并[1,5-a]吡啶-4-基)-5-甲基-4,5-二氢-3(2H)-吡啉酮）。

  公开号：

  US20080207902A1
• 作为产物：
  描述：

  2-溴-6-甲氧基吡啶 在 N-溴代丁二酰亚胺(NBS) 、 copper(l) iodide 、 四(三苯基膦)钯 、 正丁基锂 、 silica gel 、 sodium carbonate 、 potassium carbonate 、 二异丙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 4-(6-chloropyridazine-3-yl)-7-methoxy-2-isopropyl-pyrazolo[1,5-a]pyridine
  参考文献：
  名称：

  Phosphodiesterase inhibitors. Part 1: Synthesis and structure–activity relationships of pyrazolopyridine–pyridazinone PDE inhibitors developed from ibudilast

  摘要：

  Ibudilast [1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one] is a nonselective phosphodiesterase inhibitor used clinically to treat asthma. Efforts to selectively develop the PDE3- and PDE4-inhibitory activity of ibudilast led to replacement of the isopropyl ketone by a pyridazinone heterocycle. Structure-activity relationship exploration in the resulting 6-(pyrazolo[1,5-a]pyridin-3-yl)pyridazin-3(2H)-ones revealed that the pyridazinone lactam functionality is a critical determinant for PDE3-inhibitory activity, with the nitrogen preferably unsubstituted. PDE4 inhibition is strongly promoted by introduction of a hydrophobic substituent at the pyridazinone N(2) centre and a methoxy group at C-70 in the pyrazolopyridine. Migration of the pyridazinone ring connection from the pyrazolopyridine 30-centre to C-40 strongly enhances PDE4 inhibition. These studies establish a basis for development of potent PDE4-selective and dual PDE3/4-selective inhibitors derived from ibudilast. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.021

文献信息

• Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient
  申请人：Kohno Yasushi

  公开号：US20080207902A1

  公开（公告）日：2008-08-28

  Novel pyrazolopyridine-4-yl pyridazinone derivatives serve as phosphodiesterase inhibitors and are useful compounds for use in pharmaceutical products. Specifically, the compounds of the present invention are pyrazolopyridine-4-yl pyridazinone derivatives represented by the following general formula (1): (Example: 6-(2-ethyl-7-methoxy-pyrazolo[1,5-a]pyridine-4-yl)-5-methyl-4, 5-dihydro-3(2H)-pyridazinone).

  新型吡唑吡啶-4-基吡啉酮衍生物作为磷酸二酯酶抑制剂，并且是用于制药产品的有用化合物。具体来说，本发明的化合物是由以下一般式（1）表示的吡唑吡啶-4-基吡啉酮衍生物（例如：6-(2-乙基-7-甲氧基吡唑并[1,5-a]吡啶-4-基)-5-甲基-4,5-二氢-3(2H)-吡啉酮）。
• Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：US07763617B2

  公开（公告）日：2010-07-27

  Novel pyrazolopyridine-4-yl pyridazinone derivatives serve as phosphodiesterase inhibitors and are useful compounds for use in pharmaceutical products. Specifically, the compounds of the present invention are pyrazolopyridine-4-yl pyridazinone derivatives represented by the following general formula (1): (Example: 6-(2-ethyl-7-methoxy-pyrazolo[1,5-a]pyridine-4-yl)-5-methyl-4, 5-dihydro-3(2H)-pyridazinone).

  小说嘧唑吡啶-4-基吡啶酮衍生物作为磷酸二酯酶抑制剂，并且是在制药产品中使用的有用化合物。具体而言，本发明的化合物是由以下一般式(1)表示的嘧唑吡啶-4-基吡啶酮衍生物:(例子: 6-(2-乙基-7-甲氧基嘧唑[1,5-a]吡啶-4-基)-5-甲基-4,5-二氢-3(2H)-吡啶酮)。
• US7763617B2
  申请人：——

  公开号：US7763617B2

  公开（公告）日：2010-07-27
• Phosphodiesterase inhibitors. Part 1: Synthesis and structure–activity relationships of pyrazolopyridine–pyridazinone PDE inhibitors developed from ibudilast
  作者：Robert W. Allcock、Haakon Blakli、Zhong Jiang、Karen A. Johnston、Keith M. Morgan、Georgina M. Rosair、Kazuhiko Iwase、Yasushi Kohno、David R. Adams

  DOI：10.1016/j.bmcl.2011.04.021

  日期：2011.6

  Ibudilast [1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one] is a nonselective phosphodiesterase inhibitor used clinically to treat asthma. Efforts to selectively develop the PDE3- and PDE4-inhibitory activity of ibudilast led to replacement of the isopropyl ketone by a pyridazinone heterocycle. Structure-activity relationship exploration in the resulting 6-(pyrazolo[1,5-a]pyridin-3-yl)pyridazin-3(2H)-ones revealed that the pyridazinone lactam functionality is a critical determinant for PDE3-inhibitory activity, with the nitrogen preferably unsubstituted. PDE4 inhibition is strongly promoted by introduction of a hydrophobic substituent at the pyridazinone N(2) centre and a methoxy group at C-70 in the pyrazolopyridine. Migration of the pyridazinone ring connection from the pyrazolopyridine 30-centre to C-40 strongly enhances PDE4 inhibition. These studies establish a basis for development of potent PDE4-selective and dual PDE3/4-selective inhibitors derived from ibudilast. (C) 2011 Elsevier Ltd. All rights reserved.